Ani Pharmaceuticals Stock Fundamentals
| BSFA Stock | 51.00 1.00 1.92% |
ANI Pharmaceuticals fundamentals help investors to digest information that contributes to ANI Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of ANI Stock. The fundamental analysis module provides a way to measure ANI Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ANI Pharmaceuticals stock.
ANI |
ANI Pharmaceuticals Company Operating Margin Analysis
ANI Pharmaceuticals' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current ANI Pharmaceuticals Operating Margin | (0.13) % |
Most of ANI Pharmaceuticals' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ANI Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, ANI Pharmaceuticals has an Operating Margin of -0.1277%. This is 99.64% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers-Specialty & Generic industry. The operating margin for all Germany stocks is 97.68% lower than that of the firm.
ANI Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ANI Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare ANI Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ANI Pharmaceuticals competition to find correlations between indicators driving ANI Pharmaceuticals's intrinsic value. More Info.ANI Pharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ANI Pharmaceuticals' earnings, one of the primary drivers of an investment's value.ANI Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ANI Pharmaceuticals' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ANI Pharmaceuticals could also be used in its relative valuation, which is a method of valuing ANI Pharmaceuticals by comparing valuation metrics of similar companies.ANI Pharmaceuticals is rated below average in operating margin category among its peers.
ANI Fundamentals
| Return On Equity | -0.26 | |||
| Return On Asset | -0.0374 | |||
| Profit Margin | (0.24) % | |||
| Operating Margin | (0.13) % | |||
| Current Valuation | 894.88 M | |||
| Shares Outstanding | 17.45 M | |||
| Shares Owned By Insiders | 13.11 % | |||
| Shares Owned By Institutions | 75.34 % | |||
| Price To Book | 2.16 X | |||
| Price To Sales | 2.23 X | |||
| Revenue | 216.14 M | |||
| Gross Profit | 117.43 M | |||
| EBITDA | 3.12 M | |||
| Net Income | (42.6 M) | |||
| Total Debt | 286.52 M | |||
| Book Value Per Share | 19.11 X | |||
| Cash Flow From Operations | 3.32 M | |||
| Earnings Per Share | (4.46) X | |||
| Number Of Employees | 601 | |||
| Beta | 1.06 | |||
| Market Capitalization | 699.18 M | |||
| Total Asset | 771.6 M | |||
| Z Score | 1.2 | |||
| Net Asset | 771.6 M |
About ANI Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ANI Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ANI Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ANI Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.